Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
Tumori|April 26, 2007
Anxiety levels in cancer patients and "life sound" experienceEnrico Aitini, Alessia Sempreboni, Paola Aleotti, et al.Cancer Chemotherapy and Pharmacology|May 12, 2012
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyAlberto Zaniboni, Enrico Aitini, Sandro Barni, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?Diego Cortinovis, Paolo Bidoli, Daniela Cullurà, et al.Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 6, 2010
Attitude of Italian medical oncologists toward palliative care for patients with advanced cancer: results of the SIO projectSandro Barni, Marco Maltoni, Guido Tuveri, et al.European Journal of Cancer (Oxford, England : 1990)|February 1, 2015
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II studyMaria Di Bartolomeo, Andrea Ciarlo, Alessandro Bertolini, et al.Journal of the National Cancer Institute|December 8, 2005
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trialMarco Venturini, Lucia Del Mastro, Enrico Aitini, et al.Breast (Edinburgh, Scotland)|May 7, 2013
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancerMatteo Clavarezza, Monica Turazza, Enrico Aitini, et al.The Lancet. Oncology|December 14, 2007
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu, Rossana Berardi, Roberto Labianca, et al.Clinical Drug Investigation|June 12, 2008
Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational studyBarbara Silvestri, Elena Bandieri, Salvatore Del Prete, et al.Pageof 3